Tags

Type your tag names separated by a space and hit enter

Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation.
Clin Infect Dis. 2003 Mar 15; 36(6):749-58.CI

Abstract

In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m(2) q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n=83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n=85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P=.934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P=.588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation.

Authors+Show Affiliations

University of California, Center for the Health Sciences, Los Angeles, USA. dwinston@mednet.ucla.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

12627359

Citation

Winston, Drew J., et al. "Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation." Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, vol. 36, no. 6, 2003, pp. 749-58.
Winston DJ, Yeager AM, Chandrasekar PH, et al. Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clin Infect Dis. 2003;36(6):749-58.
Winston, D. J., Yeager, A. M., Chandrasekar, P. H., Snydman, D. R., Petersen, F. B., & Territo, M. C. (2003). Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America, 36(6), 749-58.
Winston DJ, et al. Randomized Comparison of Oral Valacyclovir and Intravenous Ganciclovir for Prevention of Cytomegalovirus Disease After Allogeneic Bone Marrow Transplantation. Clin Infect Dis. 2003 Mar 15;36(6):749-58. PubMed PMID: 12627359.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation. AU - Winston,Drew J, AU - Yeager,Andrew M, AU - Chandrasekar,Pranatharthi H, AU - Snydman,David R, AU - Petersen,Finn Bo, AU - Territo,Mary C, AU - ,, Y1 - 2003/03/03/ PY - 2002/06/06/received PY - 2002/12/04/accepted PY - 2003/3/11/pubmed PY - 2003/3/21/medline PY - 2003/3/11/entrez SP - 749 EP - 58 JF - Clinical infectious diseases : an official publication of the Infectious Diseases Society of America JO - Clin Infect Dis VL - 36 IS - 6 N2 - In this multicenter, randomized study, cytomegalovirus (CMV)-seropositive patients who received an allogeneic bone marrow transplant were provided high-dose intravenous acyclovir (500 mg/m(2) q8h) from the day of transplantation until engraftment. The patients were then randomly assigned to receive either oral valacyclovir, 2 g q.i.d. (n=83), or intravenous ganciclovir, 5 mg/kg q12h for 1 week, then 6 mg/kg once daily for 5 days per week (n=85), until day 100 after transplantation. CMV infection occurred in 12% of the patients who received valacyclovir and in 19% of the patients who received ganciclovir (hazard ratio [HR], 1.042; 95% confidence interval [CI], 0.391-2.778; P=.934). CMV disease developed in only 2 patients who received valacyclovir and in 1 patient who received ganciclovir (HR, 1.943; 95% CI, 0.176-21.44; P=.588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation. SN - 1537-6591 UR - https://www.unboundmedicine.com/medline/citation/12627359/Randomized_comparison_of_oral_valacyclovir_and_intravenous_ganciclovir_for_prevention_of_cytomegalovirus_disease_after_allogeneic_bone_marrow_transplantation_ L2 - https://academic.oup.com/cid/article-lookup/doi/10.1086/367836 DB - PRIME DP - Unbound Medicine ER -